Less is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2000 Apr 20

PMID 10772648

Citations 243

Authors

D Hanahan

G Bergers

E Bergsland

Affiliations

Soon will be listed here.

Citing Articles

Canine lung carcinoma-A descriptive review.

Marcinowska A, Horta R, Queiroga F, Giuliano A Front Vet Sci. 2025; 11:1464659.

PMID: 39902337 PMC: 11788302. DOI: 10.3389/fvets.2024.1464659.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Frenel J, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E J Immunother Cancer. 2025; 13(1.

PMID: 39773562 PMC: 11749830. DOI: 10.1136/jitc-2024-010708.

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.

Liu J, Zhang J, Li H, Song G, Di L, Jiang H BMC Cancer. 2025; 25(1):9.

PMID: 39754078 PMC: 11697748. DOI: 10.1186/s12885-024-13403-2.

A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer.

McGehee C, Mori Y NPJ Syst Biol Appl. 2024; 10(1):140.

PMID: 39614108 PMC: 11607384. DOI: 10.1038/s41540-024-00461-2.

The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.

Abdelrady Y, Thabet H, Sayed A Pharmacol Rep. 2024; 77(1):1-20.

PMID: 39432183 DOI: 10.1007/s43440-024-00662-w.

References

Lokich J, Anderson N . Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol. 1997; 8(1):15-25. DOI: 10.1023/a:1008243806415. View

Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A . Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol. 1996; 7(8):807-13. DOI: 10.1093/oxfordjournals.annonc.a010759. View

DAmato R, Loughnan M, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91(9):4082-5. PMC: 43727. DOI: 10.1073/pnas.91.9.4082. View

Burris H . Weekly schedules of docetaxel. Semin Oncol. 1998; 25(6 Suppl 13):21-3. View

Piedbois P, Rougier P, Buyse M, Pignon J, Ryan L, Hansen R . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1):301-8. DOI: 10.1200/JCO.1998.16.1.301. View

Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104(2):155-62. PMC: 408479. DOI: 10.1172/JCI6926. View

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D . Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000; 105(8):R15-24. PMC: 517491. DOI: 10.1172/JCI8829. View

Colleoni M, Rocca A, Sandri M, Zorzino L, Masci G, Nole F . Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13(1):73-80. DOI: 10.1093/annonc/mdf013. View

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H . Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990; 348(6301):555-7. DOI: 10.1038/348555a0. View

10.

Masferrer J, Koki A, Seibert K . COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 2000; 889:84-6. DOI: 10.1111/j.1749-6632.1999.tb08726.x. View

11.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

12.

Sorensen P, Andersen L, Hansen O, Bastholt L . Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer. Acta Oncol. 2000; 38(8):1043-5. DOI: 10.1080/028418699432338. View

13.

Benjamin L, Golijanin D, Itin A, Pode D, Keshet E . Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999; 103(2):159-65. PMC: 407882. DOI: 10.1172/JCI5028. View

14.

Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R . Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999; 94(12):4143-55. View

15.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

16.

Slaton J, Perrotte P, Inoue K, Dinney C, Fidler I . Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999; 5(10):2726-34. View

17.

Heise C, Kirn D . Replication-selective adenoviruses as oncolytic agents. J Clin Invest. 2000; 105(7):847-51. PMC: 377494. DOI: 10.1172/JCI9762. View

18.

Teicher B, Holden S, Ara G, Sotomayor E, Huang Z, Chen Y . Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer. 1994; 57(6):920-5. DOI: 10.1002/ijc.2910570624. View

19.

Witte L, Hicklin D, Zhu Z, Pytowski B, Kotanides H, Rockwell P . Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998; 17(2):155-61. DOI: 10.1023/a:1006094117427. View

20.

Blumenreich M, Sheth S, Miller C, Farnsley E, Kellihan M, Joseph U . Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer. Am J Clin Oncol. 1994; 17(2):163-5. DOI: 10.1097/00000421-199404000-00015. View